![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/mission-therapeutics-awarded-5-2m-from-the-michael-j-fox-foundation-and-parkinsons-uk-to-advance-potential-disease-modifying-treatment-mtx325--302187338.html
https://endpts.com/pfizer-backed-mission-therapeutics-raises-25m-to-advance-mitophagy-pipeline/
https://www.prnewswire.com/news-releases/mission-therapeutics-announces-us-fda-approval-to-initiate-phase-ii-clinical-trial-of-its-lead-asset-mtx652-in-acute-kidney-injury-302014249.html
https://www.prnewswire.com/news-releases/mission-therapeutics-granted-mhra-clinical-trial-authorisation-cta-for-mtx325-for-the-treatment-of-parkinsons-disease-302005510.html
https://www.prnewswire.com/news-releases/mission-therapeutics-announces-publication-in-nature-communications-outlining-potential-of-experimental-drug-mtx325-as-a-disease-modifying-therapy-for-parkinsons-disease-301984996.html
https://www.prnewswire.com/news-releases/mission-therapeutics-to-present-abstract-at-american-society-of-nephrology-asn-kidney-week-2023-301974832.html
https://www.prnewswire.com/news-releases/mission-therapeutics-to-present-at-michael-j-fox-foundations-15th-annual-parkinsons-disease-therapeutics-conference-301950882.html
https://www.pharmatimes.com/news/mission_therapeutics_concludes_clinical_assessment_for_lead_dub_inhibitor_1484967